Multiple Sclerosis Cases Surge in Mexico, Disproportionately Affecting Young Women

Multiple sclerosis is reshaping the landscape of neurological disease in Mexico, striking down young women at rates that have climbed tenfold in half a century. The disease, which attacks the central nervous system and strips away the protective coating around nerve fibers, has moved from a medical rarity to a leading cause of disability in adults under forty.

Fifty years ago, Mexico recorded barely 1.6 cases per 100,000 people. Today that number sits between 15 and 18 per 100,000—a shift that reflects not just better diagnostic tools but a genuine rise in incidence. The disease clusters unevenly across the country, with the heaviest concentrations in Mexico City, the State of Mexico, and Jalisco, straining public hospital networks already stretched thin.

The disease has a pronounced preference for women. For every man diagnosed, two to three women receive the same diagnosis, according to Mexico's health ministry and the National Autonomous University's medical faculty. The typical onset arrives between ages twenty and forty, with the peak hitting around twenty-five—precisely when women are building careers, pursuing education, and starting families. This timing amplifies the social and economic wreckage. Multiple sclerosis now stands as the primary cause of non-traumatic neurological disability in young adults, second only to traumatic injury as a source of overall disability in this age group.

The disease emerges from a collision between genetic susceptibility and environmental triggers. Researchers at Mexico's National Institute of Neurology and Neurosurgery have identified genes of European ancestry and mixed heritage as risk factors. Environmental contributors include vitamin D deficiency, prior infection with Epstein-Barr virus, smoking, and childhood obesity. Each element weakens the immune system's ability to distinguish self from invader, tipping the body into attacking its own nervous tissue. The inflammation leaves behind scar tissue visible on magnetic resonance imaging—the anatomical signature of the disease.

Early detection proves devilishly difficult because the disease announces itself differently in nearly every patient. Symptoms depend on where inflammation strikes and how severe it becomes. Optic neuritis—sudden vision loss in one eye accompanied by pain behind the eye, blurred sight, and color distortion—appears in roughly half of initial cases. When inflammation reaches the brainstem, patients experience double vision and involuntary eye movements. Sensory disturbances are common: numbness, burning, or tingling in limbs or torso. A distinctive sign called Lhermitte's phenomenon produces an electric sensation running down the spine and into the limbs when the neck bends forward. Some women develop severe facial pain from trigeminal neuralgia. Motor weakness follows, with difficulty walking, leg weakness, and muscle stiffness. Cerebellar involvement disrupts balance and coordination, sometimes affecting speech and swallowing. The autonomic nervous system can malfunction, causing urgent or retained urination. Chronic fatigue strikes eighty percent of patients—not ordinary tiredness but an incapacitating exhaustion unrelated to physical exertion, worsened by heat, often accompanied by memory loss, concentration problems, emotional instability, and depression.

Diagnosis requires excluding other diseases and proving that lesions exist scattered across both space and time, confirmed by MRI and analysis of cerebrospinal fluid for oligoclonal bands. Yet structural barriers delay diagnosis. Patients referred from general practitioners to neurologists face bureaucratic delays and widespread ignorance of early symptoms among primary care physicians, allowing irreversible nerve damage to accumulate. National clinical guidelines recommend starting disease-modifying therapy immediately after diagnosis, especially in younger patients with severe symptoms. Treatment combines steroids for acute flare-ups with close MRI monitoring, alongside physical rehabilitation, mental health support, and lifestyle changes including smoking cessation and weight management. Coordination among neurologists, physiatrists, and mental health specialists proves essential.

The economic toll extends far beyond medical bills. Lifetime treatment costs can reach millions of pesos. Unemployment among those with the disease runs high. Mexico ranks among Latin America's countries bearing the heaviest burden of disability from this condition. The central challenge lies in accelerating diagnosis, ensuring access to advanced treatments, and educating frontline physicians about the disease's varied presentations. Only coordinated action grounded in official data and national protocols can improve outcomes and reduce the disability burden falling on young Mexican women.